The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...
Investors are anticipating which sectors might be most affected by the Trump administration. Brett Friedman, Winhall Risk Analytics/OptionMetrics Contributor takes a look at options data and implied volatility...
Cencora has underperformed the broader market over the past year, and Wall Street analysts appear moderately bullish about the stock’s future.
Election Day has approached, and the polls indicate a tight race between Democratic Party candidate Kamala Harris and Republican nominee Donald Trump. Neither candidate holds a meaningful edge in enough...
Johnson & Johnson JNJ infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with...
For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...